- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05910866
LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy (LEAP-CAR)
LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy: the LEAP-CAR Prospective, Randomized Trial
LEAP-CAR will evaluate the benefit of left bundle branch area pacing (LBBAP), comparing to conventional right ventricular pacing (RVP), in preventing pacing-induced cardiomyopathy (PICM) in patients undergoing pacemaker implant for advanced (2° or 3° degree) atrioventricular block, with baseline left ventricular ejection fraction (LVEF) >45%.
LEAP-CAR is a randomized, prospective, double blind clinical trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pacing induced cardiomyopathy (PICM) is the deleterious effect of right ventricular (RV) pacing in patients receiving a permanent cardiac pacemaker (PM) for bradycardia. It is usually defined as a decrease in left ventricular (LV) function, generally expressed as ejection fraction (EF) decline, and it is mostly explained by the abnormal electrical and mechanical biventricular activation sequence induced by RV pacing. Several studies reported an incidence of PICM ranging from 10-20% of patients after 2-4 years of at least 20% RV pacing burden and reported an increase in heart failure (HF) and hospitalization in such patients.
Permanent His Bundle Pacing (HBP) maintains normal electromechanical biventricular activation by means of the intrinsic conduction system and is therefore considered in patients with EF >40% and anticipated >20% of ventricular pacing, and may be used as an alternative to CRT in case of "ablate and pace" therapy for uncontrolled supraventricular arrhythmias.
Left bundle branch area pacing (LBBAP) is a novel way to pace the conduction system of the heart, overcoming the drawbacks of HBP (suboptimal electrical measures, increased procedural and fluoroscopy time, loss of conduction system capture at follow-up). Evidence is building in adopting LBBAP instead of conventional CRT; LBBAP may have the potential to avoid PICM in patients needing permanent pacing for bradycardia.
Aim of our study is to assess if LBBAP prevents PICM in patients with preserved EF needing RV pacing for advanced atrioventricular block (AVB).
STUDY DESIGN
Single-blind, 1:1 randomized, multicenter, prospective study.
All consecutive patients with advanced AVB (frequent 2° degree or 3° degree AVB, atrial fibrillation - AF - with advanced AV block) and preserved or slightly reduced LVEF (>45%) receiving permanent PM will be randomized to LBBAP or RV (myocardial/parapical) pacing, according to a prespecified, automatically generated randomization list. The device will be implanted according to current optimal clinical practice, using clinically available stylet-driven or delivery-driven pacing leads. Choice of leads and device (single chamber in AF patients, dual chamber in sinus rhythm - SR) will be made according to operator preference and current clinical indications.
Exclusion criteria will be: LVEF ≤45%; signs or symptoms of heart failure at enrollment; unstable angina or acute coronary syndrome <3 months; percutaneous coronary intervention or coronary-artery bypass surgery <3 months; life expectancy <6 months; previous hospitalization for heart failure; evidence of pulmonary artery hypertension of any origin; valvular disease greater than moderate; previous heart transplant; pregnancy.
Baseline assessment will include: baseline ECG; echocardiography; measurement of the distance covered on a 6-minute walk (6'WT); quality-of-life assessment by Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ). All patients will receive a follow-up visit at 3 and 12 months, when ECG, electrical follow-up of the PM and assessment of adverse events will be performed; echocardiography, MLHFQ and 6'WT will be performed at 12 months. Echocardiography and 6'WT will be done by a Cardiologist unaware of the randomization assignment. Echocardiographic images will be stored and evaluated by a specialist who will be unaware of the assigned treatment.
Echocardiography will assess left ventricular function (LVEF) and volumes, preferably by automated 3D analysis. Strain analysis will be performed as adjunctive evaluation as per Center standard clinical practice; data on LV diastolic function and concomitant valve diseases will be also collected.
PMs will be programmed in both arms in DDD or DDDR mode, with fixed or rate-adaptive AV delays no longer than 180 ms and de-activating algorithms promoting spontaneous AV conduction (i.e. reverse mode change, or AV hysteresis..), in case of SR; in VVI or VVIR in case of AF.
Maintenance of unmodified pharmacological therapy will be encouraged until follow-up completion to avoid confounders.
Primary endpoint will be the comparison of LVEF by transthoracic echocardiography at 12 months between the two arms (LBBAP vs RV pacing).
Secondary endpoints will be:
- Percentages of unsuccessful procedure in the two arms (LBBAP vs RV pacing)
- Comparison of distance covered at 6'WT at 12 months between the two arms (LBBAP vs RV pacing)
- Comparison of MLHFQ score at 12 months between the two arms (LBBAP vs RV pacing)
- Comparison of variation in LVEF from baseline to 12 months in the two arms (LBBAP and RV pacing, baseline vs 12 months follow up)
- Comparison of variation in distance covered at 6'WT from baseline to 12 months between the two arms (LBBAP vs RV pacing)
- Comparison of variation in MLHFQ score from baseline to 12 months between the two arms (LBBAP vs RV pacing).
- Percentages of patients with mitral/tricuspid regurgitation at least moderate at 12 months by echocardiography in the two arms (LBBAP vs RV pacing)
Extended follow-up of 2 years will be promoted to assess development of symptomatic heart failure (i.e. any hospitalization for heart failure or starting of medications for heart failure) or mortality. This extended follow-up will not be mandatory as per protocol.
STATISTICAL ANALYSIS Data will be evaluated according to an intention to treat analysis, keeping track of treatment crossover for "per protocol" analyses, anticipating a potential failure in 3% of LBBAP group, leading to RV pacing in those patients.
Continuous variables with normal distribution will be expressed as mean +/- standard deviation (SD) and compared by two-tailed t-test; non-normally distributed variables will be expressed as median (25-75% interquartile range) and compared by Wilcoxon-Mann-Whitney test. Normality will be assessed by Kolomorgov-Smirnov test. Categorical data will be expressed as percentage and compared by chi-square test. P values <0.05 will be considered statistically significant.
SAMPLE SIZE CALCULATION
Estimating a normal mean baseline LVEF of 55% and a predicted reduction of 5% (11,1) in RV apical pacing patients comparing to LBBAP, the following calculations were made:
Continuous Endpoint, Two Independent Sample Study Sample Size Group 1 63 Group 2 63 Total 126 Study Parameters Mean, group 1 55 Mean, group 2 5010% dec Alpha 0.05 Beta 0.2 Power 0.8
Anticipating potential dropout, sample size will be rounded to 130 patients. Interim analysis will be carried out when half the sample size will complete 1-year follow-up to confirm adequacy of enrollment and to analyze the trend of the primary endpoint.
Our calculations were modeled after the PACE trial design, that assessed similar endpoints comparing CRT and RV pacing.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gabriele Dell'Era, MD
- Phone Number: +39 03213733294
- Email: gabriele.dellera@maggioreosp.novara.it
Study Contact Backup
- Name: Chiara Ghiglieno, MD
- Phone Number: +39 03213733294
- Email: chiara.ghiglieno@maggioreosp.novara.it
Study Locations
-
-
-
Novara, Italy, 28100
- Recruiting
- Hospital "Maggiore della Carità", Division of Cardiology
-
Contact:
- Gabriele Dell'Era, MD
- Phone Number: 03213733590
- Email: gabriele.dellera@maggioreosp.novara.it
-
Contact:
- Chiara Ghiglieno, MD
- Phone Number: 03213733590
- Email: chiara.ghiglieno@maggioreosp.novara.it
-
Sub-Investigator:
- Chiara Ghiglieno, MD
-
Sub-Investigator:
- Federica De Vecchi, MD
-
Sub-Investigator:
- Matteo Santagostino, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- advanced AVB (frequent 2° degree or 3° degree AVB, atrial fibrillation - AF - with advanced AV block) and preserved or slightly reduced LVEF (>45%)
Exclusion Criteria:
- LVEF ≤45%
- signs or symptoms of heart failure at enrollment
- unstable angina or acute coronary syndrome <3 months
- percutaneous coronary intervention or coronary-artery bypass surgery <3 months
- life expectancy <6 months
- previous hospitalization for heart failure
- evidence of pulmonary artery hypertension of any origin
- valvular disease greater than moderate
- previous heart transplant pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Left bundle branch area pacing (LBBAP)
Implant of the ventricular lead of the pacemaker in the left bundle branch area
|
Pacing of the conduction system of the heart to obtain physiological activation
|
Active Comparator: Right ventricular pacing (RVP)
Implant of the ventricular lead of the pacemaker in a conventional site for pacing (apex/paraapical interventricular septum)
|
Conventional ventricular pacing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute and relative value of LVEF (left ventricular ejection fraction) difference between two arms at follow-up
Time Frame: 1 year
|
comparison of LVEF by transthoracic echocardiography at 12 months between the two arms (LBBAP vs RV pacing).
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
success rate
Time Frame: 1 year
|
Percentages of unsuccessful procedure in the two arms (LBBAP vs RV pacing)
|
1 year
|
Distance covered at 6'WT (meters)
Time Frame: 1 year
|
Comparison of distance covered at 6'WT at 12 months between the two arms (LBBAP vs RV pacing)
|
1 year
|
Score of quality of life (n: Higher value = worst outcome)
Time Frame: 1 year
|
Comparison of MLHFQ score at 12 months between the two arms (LBBAP vs RV pacing)
|
1 year
|
Intra-patient evolution of LVEF
Time Frame: 1 year
|
Comparison of variation in LVEF (absolute and %) from baseline to 12 months in the two arms (LBBAP and RV pacing, baseline vs 12 months follow up)
|
1 year
|
Intra-patient evolution of 6'WT (meters difference)
Time Frame: 1 year
|
Comparison of variation in distance covered at 6'WT from baseline to 12 months between the two arms (LBBAP vs RV pacing)
|
1 year
|
Intra-patient evolution of quality of life
Time Frame: 1 year
|
Comparison of variation in MLHFQ score from baseline to 12 months between the two arms (LBBAP vs RV pacing).
|
1 year
|
evolution of atrioventricular valves regurgitation
Time Frame: 1 year
|
Percentages of patients with mitral/tricuspid regurgitation at least moderate at 12 months by echocardiography in the two arms (LBBAP vs RV pacing)
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart failure hospitalization and mortality
Time Frame: 2 years
|
any hospitalization for heart failure or starting of medications for heart failure or mortality
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CE084/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on Left bundle branch area pacing (LBBAP)
-
AZ Sint-Jan AVRecruitingHeart Failure With Reduced Ejection FractionBelgium
-
VA Office of Research and DevelopmentRecruitingHeart Failure With Reduced Ejection Fraction | Systolic Heart Failure | Left Bundle Branch Area Pacing | CRT Non-ResponseUnited States
-
Habib KhanLondon Health Sciences CentreRecruitingHeart Failure | Atrial Fibrillation | CardiomyopathiesCanada
-
Seoul National University HospitalRecruitingLeft Ventricular Ejection Fraction Less Then or Equal to 50percentKorea, Republic of
-
Fu Wai Hospital, Beijing, ChinaThe First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaboratorsRecruitingHeart Failure | Left Bundle Branch Area Pacing | Permanent Atrial Fibrillation | Biventricular PacingChina
-
Main Line HealthMedtronic; Sharpe-Strumia Research FoundationRecruitingAortic Valve Stenosis | Complete Heart Block | High Degree Second Degree Atrioventricular Block | Pacemaker-Induced CardiomyopathyUnited States
-
Fu Wai Hospital, Beijing, ChinaUnknownAtrioventricular Block | Left Bundle Branch Area PacingChina
-
Ludwig-Maximilians - University of MunichRecruitingAortic Valve Stenosis | AV Block | Pacing-Induced CardiomyopathyGermany
-
Yonsei UniversityNot yet recruitingAtrioventricular Block | Left Bundle Branch Area Pacing | BradyarrhythmiaKorea, Republic of
-
Peking Union Medical College HospitalNot yet recruitingAtrial Fibrillation | Atrioventricular Block | Left Bundle Branch Area Pacing | Right Ventricular PacingChina